FIELD: chemistry.
SUBSTANCE: invention relates to a heterocyclic compound of formula (I) or a pharmaceutically acceptable salt or ester, wherein X1: N and X2: CRx; Rx, R1 and R3: H, halogen, nitro, C1-C6alkyl, C1-C6alkyl, substituted by three halogen atoms, C1-C6alkoxy, amino, C6-C10-aryl, C6-C10-aryl substituted by 1-2 substituents selected from hydroxyl, halogen, cyano, amino, di-C1-C6alkilamino, C1-C6alkyl, C1-C6alkyl substituted by hydroxyl or amino, C1-C6alkoxy, C1-C6alkoxy substituted by three halogen atoms, C1-C6alkilkarbonyl, C1-C6alkoxykarbonyl, carboxyl, aminocarbonyl, C1-C6alkilaminokarbonyl, C1-C6alkilkarbonylamino, C1-C6alkilsulfinyl, 5-x heteroaryl containing 2 atom of N, and 5-x or 6-x heterocycle Containing 1-2 heteroatoms selected from N and O, Heteroaryl containing one or two 5-x or 6-x rings and 1-2 heteroatoms selected from N, O and S, heteroaryl containing one or two 5-x or 6-x rings and 1-2 heteroatoms selected from N and O, substituted by 1 or more substituents selected from hydroxyl, halogen, amino, C1-C6alkylcarbonyl, carboxyl, C1-C6alkyl and a 6-x heterocycle containing 2 heteroatoms selected from N and O, C3-C6 saturated carbocycle or 6-membered A heterocycle containing 1 N atom; X or y is 0 or 1; Rp1: halogen; Rp2: C1-C6alkyl or 5-x heteroaryl containing 2 heteroatoms selected from N and O; Rn5 and Rn6: H or S(O)2R8; R8: H or C1-C6alkyl; R: H, halogen, C1-C6alkyl, C1-C6alkyl, substituted by amino, C1-C6alkoxy, amino, 5-x heteroaryl containing 2-3 heteroatoms selected from N, C3-C6saturated carbocycle, C3-C6 saturated carbocycle substituted by one A substituent selected from amino, C1-C6alkoxycarbonyl, C1-C6alkylaminocarbonyl, carboxyl, and aminocarbonyl, a heterocycle containing one 4-x or 6-x ring and 1-2 heteroatoms selected from N, A heterocycle containing one 4-, 5-x or 6-x ring and 1-2 heteroatoms selected from N, O and S substituted with one substituent selected from methyl and amino or Q-T; Q: connection or C1-C6alkyl linker; T: NRn1Rn2, C(O)Ro, or S(O)2Rs; Rn1: H; Rn2: H, C1-C6alkyl, C1-C6alkyl substituted by C6-C10aryl, C(O)R4, C(O)OR4, C(O)NR4'R4, or S(O)2R5 or Rn1 and Rn2, together with the nitrogen atom to which they are attached form a 6-x ring, which optionally contains 1 additional O atom; R4, R4', and R5: H, C1-C6alkyl, C1-C6alkyl substituted by 1-2 substituents independently selected from C6-C10aryl, 5-x or 6-x heteroaryl containing 1 to 4 N atoms and C3 to C6 saturated carbocycle, C6-C10aryl, C6-C10aryl substituted by 1-2 substituents independently selected from halo, cyano, C1-C6alkyl, C1-C6alkyl substituted with three halogen atoms or with one phenyl, C1-C6alkoxy, C1-C6alkoxy substituted with three atoms of halogen, C1-C6alkilamino, di-C1-C6alkilamino, C6-C10arilkarbonyl wherein aryl is substituted by halogen, C1-C6alkoksikarbonyl, C1-C6alkilkarbonylamine, C6-C10-aryl and 5-h ennogo heteroaryl containing 1 or 2 N atoms, heteroaryl containing one or two 5-x or 6-x rings and 1-2 heteroatoms selected from N, O and S, heteroaryl containing one or two 5- or 6-membered rings and 1-2 heteroatoms selected from N, O and S, substituted with 1 or 2 substituents independently selected from halogen and C1-C6 alkyl, or C3-C6 saturated carbocycle; Ro: C6-C10aryl, NRo1Ro2, or ORo3; Rs: a 6-x heterocycle containing 1 N atom, or NRs1Rs2; Ro1 and Ro2: H, C1-C6alkyl, C1-C6alkyl substituted by 1 substituent selected from C3-C8 saturated carbocycle, C6-C10 aryl, and C1-C6alkylcarbonylamino, C6-C10aryl, C6-C10aryl substituted by one or two substituents, Independently selected from halogen, cyano, C1-C6alkyl, C1-C6alkoxy and C1-C6alkylcarbonylamino, heteroaryl containing one or two 5-x or 6-x rings and 1 heteroatom selected from N or O, heteroaryl containing one or two 5-x or 6-x rings and 1-2 heteroatoms selected from N and S substituted with one substituent selected from halogen and C1-C6alkyl or C3-C6 A saturated carbocycle; Ro3: H or C1-C6alkyl; And Rs1 and Rs2: H or C1-C6alkyl. The invention also relates to specific compounds, pharmaceutical compositions based on compounds of formula (I)
a method of treating a cell proliferative disorder.
EFFECT: obtaining novel heterocyclic compounds, useful in the treatment of bacterial infections.
21 cl, 4 tbl, 134 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COLONY-STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | 2016 |
|
RU2748884C2 |
| TRICYCLIC JANUS KINASE 1 INHIBITORS, COMPOSITIONS, METHODS OF PRODUCTION AND USE THEREOF | 2019 |
|
RU2824349C2 |
| COMPOSITIONS AND METHODS WHICH CAN BE USED FOR TREATING PROLIFERATIVE DISEASES | 2015 |
|
RU2711500C2 |
| COMPOUNDS FOR THE TREATMENT OF CERTAIN LEUKOSIS | 2019 |
|
RU2804709C2 |
| COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARISATION AND RELATED DISEASES | 2011 |
|
RU2600794C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | 2015 |
|
RU2733400C2 |
| SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE FOR TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2773333C2 |
| IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2695664C1 |
| IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS | 2011 |
|
RU2565034C2 |
| CGRP RECEPTOR ANTAGONISTS | 2004 |
|
RU2308458C2 |
